MedPath

Extension 1 to Protocol CSPP100A2340: Study to Evaluate the Efficacy and Safety of Aliskiren on the Prevention of Left Ventricular Remodeling in High Risk Post-Acute Myocardial Infarction Patients When Added to Optimized Standard Therapy

Phase 3
Completed
Conditions
Health Condition 1: null- Myocardial Infarction
Registration Number
CTRI/2009/091/000198
Lead Sponsor
Medical Dept Sandoz House Shiv Sagar Estate Dr Annie Besant Road Worli Mumbai
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
500
Inclusion Criteria

1. Patients that complete the CSPP100A2340 â??Coreâ?? study through Visit 10, while on

double-blind study drug.

2. Patients who are able to participate in the study, and who consent to do so after the

purpose and nature of the study has been clearly explained to them (written informed

consent).

Exclusion Criteria

1. NYHA class IV Congestive Heart Failure at Visit 1 (CSPP100A2340 â??Coreâ?? Study Visit

10).

2. Symptomatic hypotension, or reported systolic BP 90 mmHg within the 24 hours prior

to Visit 1 (CSPP100A2340 â??Coreâ?? Study Visit 10).

3. Known Estimated Glomerular Filtration Rate (eGFR) 30 ml/min/1.73m2 using the

MDRD formula at Visit 1 (CSPP100A2340 â??Coreâ?? Study Visit 10).

4. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female

after conception and until the termination of gestation, confirmed by a positive hCG

laboratory test ( 5 mIU/ml).

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
?Adverse events at each visitTimepoint: Time Frame: 24 months
Secondary Outcome Measures
NameTimeMethod
?Echocardiography (left ventricular end systolic volume, left ventricular end diastolic volume, left ventricular ejection fraction) at 12 monthsTimepoint: Time Frame: 24 months;ECG at 12 and 24 monthsTimepoint: Time Frame: 24 months;Laboratory evaluations at each visitTimepoint: Time Frame: 24 months;Vital signs (blood pressure, heart rate) at each visitTimepoint: Time Frame: 24 months
© Copyright 2025. All Rights Reserved by MedPath